ClinicalTrials.gg
Active, not recruitingNCT07425821Updated Oct 30, 2026

A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

A Phase 1 interventional study of rVSV∆G-MARV-GP and Placebo in Marburg Virus Disease, sponsored by International AIDS Vaccine Initiative. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by International AIDS Vaccine Initiative · Phase 1, Interventional, and Prevention

How we know

Updated Oct 30, 2026Now Active, not recruitingStudy documents postedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Read the detailed description

This is a observer-blind, Phase 1 Randomized, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health. The study is a dose escalation study that will administer 4 different dose levels to 4 different groups. The lowest dose level will be given and then a safety assessment will occur before escalation to the next dose level. This gradual dosing followed by a safety assessment will be repeated at each dose level.

Approximately 112 participants will be given vaccine (rVSV∆G-MARV-GP) or placebo.

This IAVI C104 study will look at the safety, tolerability and immunogenicity of the rVSV Marburg virus vaccine.

02

Conditions studied

  • Marburg Virus Disease
03

In context

Lead sponsor

International AIDS Vaccine Initiative is the lead sponsor of 37 studies on the registry; 5 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults in good general health
  2. Participants who are 18 to 50 years of age
  3. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study
  4. Willing to undergo testing, risk reduction counseling, and receive HIV test results
  5. All sexually active participants must consistently use male or female condoms with all sexual partners for 3 months following IP administration
  6. All individuals of engaging in sexual activity that could lead to pregnancy must commit to use an effective method of from at least 2 weeks before and continue until 3 months following receipt of vaccine/placebo
  7. All individuals of childbearing potential must be willing to undergo urine pregnancy tests at time points indicated in the Schedule of Activities (SOA)
  8. All participants must be willing to forgo donation of blood or any other tissues from screening onward throughout the course of the study

Exclusion criteria

Exclusion Criteria

  1. Any abnormality on history or examination including:

    history of immunodeficiency or disease history of splenectomy history of in the past 5 years use of , , anticancer, or other medications considered significant by the Investigator within the previous 6 months (BMI) ≥ 35.0 kg/m2

  2. Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the Investigator makes the participant unsuitable for participation in the study
  3. Individuals who are pregnant or breastfeeding
  4. Bleeding disorder that was diagnosed by a physician
  5. Infectious disease: Confirmed -1 or HIV-2 infection, chronic active infection, current infection, active syphilis, or medically diagnosed long COVID 19 Syndrome. Also excluded are participants with active, serious infections requiring parenteral antibiotic, antiviral, or antifungal therapy within 30 days prior to enrollment.
  6. Any abnormal laboratory parameters at screening per protocol.
  7. Receipt of live attenuated influenza vaccine within the previous 14 days, any other within the previous 30 days or planned receipt within 30 days after vaccination with IP; or receipt of non-live attenuated vaccine within the previous 14 days or planned receipt within 14 days after vaccination with IP, including COVID-19 vaccines
  8. Receipt of blood transfusion or blood-derived products within the previous 3 months
  9. Prior potential exposure to Marburg Virus, or a medical history of hemorrhagic fever
  10. Prior receipt of any VSV-vectored vaccine, any Marburg vaccine, or any vaccine containing a filovirus component. Prior receipt of monoclonal or polyclonal antibodies directed against Marburg or other filovirus in the past 12 months
  11. Current participation in another clinical trial, within 3 months prior to enrollment.
  12. History of severe local or systemic reactogenicity to vaccines, or severe allergy to food or medications, and/or allergy to any component of this vaccine.
  13. Neuropsychiatric condition or substance abuse that compromises safety of the participant and precludes compliance with the protocol
  14. Current or planned occupational (medical care, childcare) or household contact (residing in the same household) from screening through 3 months after IP administration with any individual at increased risk from exposure to a live viral vaccine including infants ≤ 1 year of age, adults ≥75 years of age, or immunocompromised individuals.
  15. In the opinion of the PI, it is not in the best interest of the participant to participate in the trial
  16. A history of long-term treatment (≥ 4 weeks) for arthritis
  17. Participants currently experiencing a rash or who have a history of severe, chronic, or frequent rash will be excluded.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    rVSV∆G-MARV-GP

    Biological: rVSV∆G-MARV-GP

  • Placebo comparator
    Placebo/Diluent

    Other: Placebo

Interventions

  • BiologicalrVSV∆G-MARV-GP

    rVSV∆G-MARV-GP

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of rVSV∆G-MARV-GP vaccination: solicited reactogenicity

    Occurrence, onset, duration, and severity of local and systemic solicited adverse events within 14 days following vaccination

    Time frame: 14 Days

  2. Safety and tolerability of rVSV∆G-MARV-GP vaccination: unsolicited reactogenicity

    Occurrence, onset, duration, severity, and relationship to IP of unsolicited adverse events, including safety laboratory parameters, within 28 days following vaccination

    Time frame: 28 days

  3. Safety and tolerability of rVSV∆G-MARV-GP vaccination: SAEs and AESIs

    Occurrence, onset, duration, severity, and relationship to IP of SAEs and AESIs throughout the study period

    Time frame: 7 Months

Secondary outcomes

  1. MARV-GP-specific serum antibody responses

    Proportion of participants with binding antibody responses to MARV-GP

    Time frame: Throughout the study, up to 6 months after immunisation

  2. MARV-GP-specific serum antibody responses magnitude and duration

    Magnitude and duration of binding antibody to MARV-GP throughout the full study period (1 week, 2 weeks, 4 weeks, 2 months, 3 months, 6 months after immunization)

    Time frame: Throughout the study, up to 6 months after immunisation

  3. MARV-GP-specific serum antibody neutralization

    Proportion of participants with neutralizing antibody against Marburg virus as measured by PRNT assay

    Time frame: Throughout the study, up to 6 months after immunisation

  4. MARV-GP-specific serum antibody magnitude and duration of neutralization

    Magnitude and duration of neutralizing antibody against Marburg virus as measured by PRNT assay throughout the full study period (1 week, 2 weeks, 4 weeks, 2 months, 3 months, 6 months after immunization)

    Time frame: Throughout the study, up to 6 months after immunisation

07

Study locations

2 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 23, 2026
StartActual
Mar 27, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Oct 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 30, 2026
Documents
Show all 1 update
  1. Oct 30, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07425821
Lead sponsor
International AIDS Vaccine Initiative
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Mar 27, 2026
Primary completion
Apr 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion